Selenium Deficiency and Muscle Growth: Clinical Significance
Selenium deficiency does not cause clinically significant reductions in muscle growth in humans, despite causing severe nutritional muscular dystrophy in animals. The most compelling human evidence shows that even severely selenium-depleted patients on long-term parenteral nutrition maintain normal cardiac function and lack clinically significant skeletal myopathy 1.
Key Evidence from Human Studies
The critical distinction lies between animal models and human clinical outcomes. While animal studies demonstrate dramatic muscle pathology with selenium deficiency—including reduced muscle fiber area, impaired differentiation, and nutritional muscular dystrophy 2, 3, 4—the human data tells a fundamentally different story.
In the highest-quality human study, 10 severely selenium-depleted patients (median plasma selenium 0.21 μmol/L, well below the 0.75 μmol/L threshold) on long-term home parenteral nutrition underwent comprehensive muscle evaluation including:
- Skeletal muscle biopsies
- Muscle force testing (Kin-Com dynamometry)
- Electromyography
- Cardiac function assessment
Results showed normal cardiac function, no clinically significant skeletal myopathy, and unchanged muscle strength despite severe depletion 1. The only detectable change after selenium repletion was a small but statistically significant increase in mean diameter of type 1 muscle fibers—a subclinical finding without functional impact.
Clinical Context and Guidelines
The 2022 ESPEN Micronutrient Guidelines provide the framework for understanding selenium's role 5:
Threshold values for intervention:
- Plasma selenium <0.4 μmol/L (<32 mg/L): Always triggers supplementation
- Plasma selenium <0.75 μmol/L (without inflammation): Should prompt supplementation to prevent non-specific consequences like impaired immune function
Critical caveat: The guidelines emphasize that selenium's primary clinical concerns relate to immune function and viral infection susceptibility 5, not muscle growth or function.
Why the Animal-Human Discrepancy Matters
Animal models consistently show:
- Reduced myofiber area and nuclei 3
- Massive skeletal muscle cell apoptosis 3
- Impaired muscle cell differentiation 2, 3
- Oxidative stress with elevated ROS and MDA 3
- Downregulation of differentiation genes (Myog, Myod, Myh2, Myh3) 3
However, these findings do not translate to clinically meaningful muscle dysfunction in humans at the selenium levels typically encountered in clinical practice.
Practical Clinical Approach
When to measure selenium:
- Patients on parenteral nutrition >2 weeks 5
- Age ≥75 years (91.7% sensitivity for detecting low selenium) 6
- Prolonged tube feeding 6
- Hemodialysis patients 6
When to supplement:
Immediate supplementation: Plasma selenium <0.4 μmol/L
- Start 100 mg/day (enteral or IV)
- For severe deficiency (<0.4 μmol/L): IV route with up to 400 mg/day for 7-10 days 5
Preventive supplementation: Plasma selenium <0.75 μmol/L (without inflammation, CRP <20 mg/L)
- Basic requirement: 60-100 mg/day 5
Special populations requiring higher doses:
- Burns patients: 375 mg/day (improves wound healing, reduces infections) 5
- Major trauma/cardiac surgery: 275 mg/day 5
- Renal replacement therapy: Increased amounts due to losses 5
Important Caveats
Inflammation confounds interpretation: CRP levels significantly affect plasma selenium:
- CRP 10-40 mg/L: 15-25% reduction in plasma selenium
- CRP 41-80 mg/L: ~35% reduction
- CRP >80 mg/L: ~50% reduction 5
Always measure CRP simultaneously with selenium to avoid misinterpreting inflammation-induced redistribution as true deficiency 5.
Avoid excessive supplementation: Meta-analyses show no benefit from high-dose selenium (1000-4000 mg/day) in ICU patients 5, and selenium overexposure associates with type 2 diabetes and high-grade prostate cancer 5.
Bottom Line for Clinical Practice
While selenium deficiency requires correction to prevent immune dysfunction and other systemic effects, concerns about clinically significant muscle growth impairment in humans are not supported by the evidence. Focus selenium monitoring and supplementation on high-risk populations (parenteral nutrition, elderly, specific disease states) using guideline-recommended thresholds, but do not expect meaningful improvements in muscle mass or strength from selenium repletion alone in deficient patients.